Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kymera Therapeutics Inc (NQ: KYMR )

42.00 -1.10 (-2.55%)
Streaming Delayed Price Updated: 11:23 AM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 119,856
Open 43.48
Bid (Size) 41.93 (1)
Ask (Size) 42.10 (4)
Prev. Close 43.10
Today's Range 41.84 - 43.48
52wk Range 9.600 - 48.70
Shares Outstanding 55,307,775
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit... 
Via Benzinga
Why Kymera Therapeutics Stock Is Soaring Today
Kymera's lead pipeline candidate received some good news. 
Via The Motley Fool

Performance

YTD
+65.68%
+65.68%
1 Month
+31.29%
+31.29%
3 Month
+22.27%
+22.27%
6 Month
+43.39%
+43.39%
1 Year
+91.78%
+91.78%

More News

Read More
Why Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Kymera Therapeutics
Via Benzinga
Demystifying Kymera Therapeutics: Insights From 5 Analyst Reviews
Via Benzinga
Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Via Benzinga
Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
Via FinancialNewsMedia
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
From FN Media Group LLC
Via GlobeNewswire
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Participate in Upcoming June Investor Conferences
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
From Kymera Therapeutics, Inc.
Via GlobeNewswire
KYMR Stock Earnings: Kymera Therapeutics Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Piper Sandler Maintains Overweight Rating for Kymera Therapeutics: Here's What You Need To Know
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.